Abstract
Incidence of infective endocarditis (IE) is progressively raising because of the increasing number of cardiovascular invasive procedures, support treatment and devices, awareness in the medical community and improved diagnostic modalities. IE pathophysiology is a unique model of immunothrombosis and the clinical course is often complicated by either thromboembolic or hemorrhagic events. Managing antithrombotic treatment is challenging and the level of supporting evidence scant. Aim of this review was to discuss and present the thromboembolic and bleeding complication associated with IE and review the available evidence on anti-thrombotic treatment in patients with IE with and without a previous indication to anti-thrombotic drugs.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
